Europe Transparency Initiatives May Aid Progress Toward Adaptive Licensing Systems
Industry and regulators are showing more interest in implementing adaptive licensing in Europe. Both sides agree that increased trust and transparency could be stepping stones towards this goal.
You may also be interested in...
Most European health care stakeholders agree that adaptive licensing will improve access and promote innovation, but are undecided which drugs would qualify.
European Notebook: Revolutionary Change Needed for European Biotech; CHMP Releases Opinions Agenda; Growing Interest In Biosimilars
Radical change urged to help Europe compete in biotech; CHMP becomes less secretive over its meeting agendas; Almirall restructures its European business and buys U.S. dermatology business; biosimilar biologics companies, Almotech and Samsung Bioepis, target Europe.
Drug manufacturers say the announced two-year extension for Britain’s Cancer Drugs Fund would not have been needed if NICE was not so focused on cost.